Genetic diversity and selective pressure in hepatitis C virus genotypes 1–6: Significance for direct-acting antiviral treatment and drug resistance

Viruses

Volumn 7, Issue 9, 2015, Pages 5018-5039

  Cuypers, Lize ^a   Li, Guangdi ^a,b   Libin, Pieter ^a,c   Piampongsant, Supinya ^d   Vandamme, Anne Mieke ^a,e   Theys, Kristof ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

Author keywords

Direct acting antiviral treatment; Diversity; Drug resistance; Genotypes; HCV; Primers

Indexed keywords

AMINO ACID; ASUNAPREVIR; BECLABUVIR; BOCEPREVIR; DACLATASVIR; DASABUVIR; GLYCOPROTEIN E1; GLYCOPROTEIN E2; LEDIPASVIR; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; NUCLEOTIDE; OMBITASVIR; PARITAPREVIR; SIMEPREVIR; TELAPREVIR; ANTIVIRUS AGENT; NS-5 PROTEIN, HEPATITIS C VIRUS; NS3 PROTEIN, HEPATITIS C VIRUS; VIRAL PROTEIN; VIRUS RNA;

AMINO ACID SEQUENCE; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; ARTICLE; CONSENSUS SEQUENCE; GENETIC ANALYSIS; GENETIC SELECTION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; HUMAN; NONHUMAN; PEPTIDE MAPPING; PRESSURE; SELECTIVE PRESSURE; SEQUENCE ANALYSIS; ANTIVIRAL RESISTANCE; BIOLOGY; CLASSIFICATION; DNA SEQUENCE; DRUG EFFECTS; GENETIC VARIATION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC;

ANTIVIRAL AGENTS; COMPUTATIONAL BIOLOGY; DRUG RESISTANCE, VIRAL; GENETIC VARIATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; RNA, VIRAL; SELECTION, GENETIC; SEQUENCE ANALYSIS, DNA; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84941925149     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v7092857     Document Type: Article

References (90)

1. Hauri, A.M.; Armstrong, G.L.; Hutin, Y.J. The global burden of disease attributable to contaminated injections given in health care settings. Int. J. STD AIDS 2004, 15, 7–16.
2. Bartosch, B.; Dubuisson, J.; Cosset, F.L. Infectious hepatitis C virus pseudo-particles containing functional E1–E2 envelope protein complexes. J. Exp. Med. 2003, 197, 633–642.
3. Abdel-Hakeem, M.S.; Shoukry, N.H. Protective immunity against hepatitis C: Many shades of gray. Front. Immunol. 2014, 5
4. Smith, D.B.; Bukh, J.; Kuiken, C.; Muerhoff, A.S.; Rice, C.M.; Stapleton, J.T.; Simmonds, P. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource. J. Hepatol. 2014, 59, 318–327.
5. Simmonds, P. Variability of hepatitis C virus. Hepatology 1995, 21, 570–583
6. Bukh, J.; Miller, R.H.; Purcell, R.H. Genetic heterogeneity of hepatitis C virus: Quasispecies and genotypes. Semin. Liver Dis. 1995, 15, 41–63.
7. Messina, J.P.; Humphreys, I.; Flaxman, A.; Brown, A.; Cooke, G.S.; Pybus, O.G.; Barnes, E. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015, 61, 77–87.
8. Le Guillou-Geuillemette, H.; Vallet, S.; Gaudy-Graffin, C.; Payan, C.; Pivert, A.; Goudeau, A.; Lunel-Fabiani, F. Genetic diversity of the hepatitis C virus: Impact and issues in the antiviral therapy. World J. Gastroenterol. 2007, 13, 2416–2462.
9. Drummer, H.E. Challenges to the development of vaccines to hepatitis C virus that elicit neutralizing antibodies. Front. Microbiol. 2014, 5.
10. Liang, T.J. Current progress in development of hepatitis C virus vaccines. Nat. Med. 2013, 19, 869–876.
11. Swadling, L.; Capone, S.; Antrobus, R.D.; Brown, A.; Richardson, R.; Newell, E.W.; Halliday, J.; Kelly, C.; Bowen, D.; Fergusson, J. et al. A human vaccine strategy based on chimpanzee adenoviral andMVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci. Transl. Med. 2014, 6, 261.
12. Hofmann, W.P.; Zeuzem, S. A new standard of care for the treatment of chronic HCV infection. Nat. Rev. Gastroenterol. Hepatol. 2011, 8, 257–264.
13. Zeuzem, S.; Andreone, P.; Pol, S.; Lawitz, E.; Diago, M.; Roberts, S.; Focaccia, R.; Younossi, Z.; Foster, G.R.; Horban, A. et al. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 2011, 364, 2417–2428.
14. Sullivan, J.C.; De Meyer, S.; Bartels, D.J.; Dierynck, I.; Zhang, E.Z.; Spanks, J.; Tigges, A.M.; Thys, A.; Dorrian, J.; Adda, N. et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin. Infect. Dis. 2013, 57, 221–229
15. Pawlotsky, J.-M. EASL Recommendations on Treatment of Hepatitis C; ILC2015: Vienna, Austria; 24; April; 2015.
16. Jacobson, I.M.; Dore, G.J.; Foster, G.R.; Fried, M.W.; Radu, M.; Rafalsky, V.V.; Moroz, L.; Craxi, A.; Peeters, M.; Lenz, O. et al. Simeprevir with pegylated interferon alpha 2a plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): A phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014, 384, 403–413.
17. Lawitz, E.; Mangia, A.; Wyles, D.; Rodriguez-Torres, M.; Hassanein, T.; Gordon, S.C.; Schultz, M.; Davis, M.N.; Kayali, Z.; Reddy, K.R. et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N. Engl. J. Med. 2013, 368, 1878–1887
18. Nelson, D.R.; Cooper, J.N.; Lalezari, J.P.; Lawitz, E.; Pockros, P.J.; Gitlin, N.; Freilich, B.F.; Younes, Z.H.; Harlan, W.; Ghalib, R. et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015, 61, 1127–1135
19. Franco, S.; Tural, C.; Nevot, M.; Molto, J.; Rockstroh, J.K.; Clotet, B.; Martinez, M.A. Detection of a sexually transmitted hepatitis C virus protease inhibitor-resistance variant in a human immunodeficiency virus-infected homosexual man. Gastroenterology 2014, 174, 599–601.
20. De Vos, A.S.; Kretzschmar, M.E.E. Benefits of hepatitis C virus treatment: A balance of preventing onward transmission and re-infection. Math. Biosci. 2014, 258, 8–11
21. Martin, T.C.; Martin, N.K.; Hickman, M.; Vickerman, P.; Page, E.E.; Everett, R.; Gazzard, B.G.; Nelson, M. Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. AIDS 2013, 27, 2551–2557
22. Micallef, J.M.; Macdonald, V.; Jauncey, M.; Amin, J.; Rawlinson, W.; van Beek, I.; Kaldor, J.M.; White, P.A.; Dore, G.J. High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. J. Viral. Hepat. 2007, 14, 413–418.
23. Vandamme, A.M.; Camacho, R.J.; Ceccherini Silberstein, F.; De Luca, A.; Palmisano, L.; Paraskevis, D.; Paredes, R.; Poljak, M.; Schmit, J.-C.; Soriano, V. et al. European recommendations for the clinical use of HIV drug resistance testing: 2011 update. AIDS Rev. 2011, 13, 77–108.
24. Sarrazin, C.; Kieffer, T.L.; Bartels, D.; Hanzelka, B.; Müh, U.; Welker, M.; Wincheringer, D.; Zhou, Y.; Chu, H.M.; Lin, C. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007, 132, 1767–1777
25. Bartels, D.J.; Zhou, Y.; Zhang, E.Z.; Marcial, M.; Byrn, R.A.; Pfeiffer, T.; Tigges, A.M.; Adiwijaya, B.S.; Lin, C.; Kwong, A.D. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naïve subjects. J. Infect. Dis. 2008, 198, 800–807
26. Lenz, O.; Verbinnen, T.; Fevery, B.; Tambuyzer, L.; Vijgen, L.; Peeters, M.; Buelens, A.; Ceulemans, H.; Beumont, M.; Picchio, G. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies. J. Hepatol. 2015, 62, 1008–1014
27. Sarrazin, C.; Lathouwers, E.; Peeters, M.; Daems, B.; Buelens, A.; Witek, J.; Wyckmans, Y.; Fevery, B.; Verbinnen, T.; Ghys, A. et al. Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region. Antivir. Res. 2015, 116, 10–16.
28. Afdhal, N.; Reddy, K.R.; Nelson, D.R.; Lawitz, E.; Gordon, S.C.; Schiff, E.; Nahass, R.; Ghalib, R.; Gitlin, N.; Herring, R. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N. Engl. J. Med. 2014, 370, 1483–1493
29. Donaldson, E.F.; Harrington, P.R.; O’Rear, J.J.; Naeger, L.K. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology 2015, 61, 56–65.
30. Bukh, J.; Purcell, R.H.; Miller, R.H. Importance of primer selection for the detection of hepatitis C virus RNA with the polymerase chain reaction assay. Proc. Natl. Acad. Sci. USA 1992, 89, 187–191
31. Jacka, B.; Lamoury, F.; Simmonds, P.; Dore, G.J.; Grebely, J.; Applegate, T. Sequencing of the hepatitis C virus: A systematic review. PLoS ONE 2013, 8.
32. Salemi, M.; Vandamme, A.M. Hepatitis C virus evolutionary patterns studied through analysis of full-genome sequences. J. Mol. Evol. 2002, 54, 62–70.
33. Li, G.; Piampongsant, S.; Faria, N.R.; Voet, A.; Pineda-Peña, A.C.; Khouri, R.; Lemey, P.; Vandamme, A.M.; Theys, K. An integrated map of HIV genome-wide variation from a population perspective. Retrovirology 2015, 12, 18.
34. Barth, H. Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade. World J. Hepatol. 2015, 7, 725–737.
35. Li, G.; Verheyen, J.; Rhee, S.Y.; Voet, A.; Vandamme, A.M.; Theys, K. Functional conservation of HIV-1 Gag: Implications for rational drug design. Retrovirology 2013, 10, 126.
36. Alcantara, L.C.; Cassol, S.; Libin, P.; Deforche, K.; Pybus, O.G.; van Ranst, M.; Galvão-Castro, B.; Vandamme, A.M.; de Oliveira, T. A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequences. Nucleic Acids Res. 2009, 37, W634–W642.
37. Margeridon-Thermet, S.; Shafer, R.W. Comparison of the mechanisms of drug resistance among HIV, Hepatitis B, and Hepatitis C. Viruses 2010, 2, 2696–2739.
38. Echevarría, J.M.; Avellón, A. Hepatitis B virus genetic diversity. J. Med. Virol. 2006, 78 (Suppl. 1), 36–42
39. Yusim, K.; Fisher, W.; Yoon, H.; Thurmond, J.; Fenimore, P.W.; Lauer, G.; Korber, B.; Kuiken, C. Genotype 1 and global hepatitis C T-cell vaccines designed to optimize coverage of genetic diversity. J. Gen. Virol. 2010, 91, 1194–1206.
40. Suzuki, Y.; Gojobori, T. Positively selected amino acid sites in the entire coding region of hepatitis C virus subtype 1b. Gene 2001, 279, 83–87.
41. Sheridan, I.; Phybus, O.G.; Holmes, E.C.; Klenerman, P. High-resolution phylogenetic analysis of hepatitis C virus adaptation and its relationship to disease progression. J. Virol. 2004, 78, 3447–3454.
42. Gray, R.R.; Parker, J.; Lemey, P.; Salemi, M.; Katzourakis, A.; Pybus, O.G. The mode and tempo of hepatitis C virus evolution within and among hosts. BMC Evol. Biol. 2011, 11.
43. Thomson, E.C.; Smith, J.A.; Klenerman, P. The natural history of early hepatitis C virus evolution; lessons from a global outbreak in human immunodeficiency virus-1-infected individuals. J. Gen. Virol. 2011, 92, 2227–2236.
44. Blackard, J.T.; Yang, Y.; Bordoni, P.; Sherman, K.E.; Chung, R.T. Hepatitis C virus (HCV) diversity in HIV-HCV-coinfected subjects initiating highly active antiretroviral therapy. J. Infect. Dis. 2004, 189, 1472–1481.
45. Kimura, M. Evolutionary rate at the molecular level. Nature 1968, 217, 624–626.
46. Holmes, E.C. Error thresholds and the constraints to RNA virus evolution. Trends Microbiol. 2003, 11, 543–546
47. Snoeck, J.; Fellay, J.; Bartha, I.; Douek, D.C.; Telenti, A. Mapping of positive selection sites in the HIV-1 genome in the context of RNA and protein structural constraints. Retrovirology 2011, 8, 87.
48. Ashfaq, U.A.; Javed, T.; Rehman, S.; Nawaz, Z.; Riazuddin, S. An overview of HCV molecular biology, replication and immune responses. Virol. J. 2011, 8, 161
49. Tan, S.-L. Chapter 1: Hepatitis C viruses: genomes and molecular biology. Horiz. Biosci. 2006, 3–10
50. Pantua, H.; Diao, J.; Ultsch, M.; Hazen, M.; Mathieu, M.; McCutcheon, K.; Takeda, K.; Date, S.; Cheung, T.K.; Phung, Q. et al. Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies. J. Mol. Biol. 2013, 425, 1899–1914
51. Penin, F.; Combet, C.; Germanidis, G.; Frainais, P.O.; Deléage, G.; Pawlostky, J.M. Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment. J. Virol. 2011, 75, 5703–5710.
52. Clark, V.C.; Peter, J.A.; Nelson, D.R. New therapeutic strategies in HCV: Second-Generation protease inhibitors. Liver Int. 2013, 33 (Suppl. 1), 80–84
53. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J. Hepatol. 2015, S0168–S8278.
54. Pol, S.; Vallet-Pichard, A.; Corouge, M. Treatment of hepatitis C virus genotype 3-infection. Liver Int. 2014, 34 (Suppl. 1), 18–23.
55. Chatel-Chaix, L.; Baril, M.; Lamarre, D. Hepatitis C virus NS3/4A protease inhibitors: A light at the end of the tunnel. Viruses 2010, 2, 1752–1765.
56. Ascher, D.B.; Wielens, J.; Nero, T.L.; Doughty, L.; Morton, C.J.; Parker, M.W. Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA. Sci. Rep. 2014
57. Lambert, S.M.; Langley, D.R.; Garnett, J.A.; Angell, R.; Hedgethorne, K.; Meanwell, N.A.; Matthews, S.J. The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors. Protein Sci. 2014, 23, 723–734
58. Nettles, J.H.; Stanton, R.A.; Broyde, J.; Amblard, F.; Zhang, H.; Zhou, L.; Shi, J.; McBrayer, T.R.; Whitaker, T.; Coats, S.J. et al. Asymmetric binding to NS5A by daclatasvir (BMS-790052) and analogues suggests two novel modes of HCV inhibition. J. Med. Chem. 2014, 57, 10031–10043
59. Yamasaki, L.H.T.; Arcuri, H.A.; Jardim, A.C.G.; Bittar, C.; de Caravalho-Mello, I.M.V.G.; Rahal, P. New insights regarding HCV-NS5A structure/function and indication of genotypic differences. Virol. J. 2012, 9.
60. Nettles, R.E.; Gao, M.; Bifano, M.; Chung, E.; Persson, A.; Marbury, T.C.; Goldwater, R.; DeMicco, M.P.; Rodriguez-Torres, M.; Vutikullird A., et al. Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 2011, 54, 1956–1965.
61. Fridell, R.A.; Qiu, D.; Wang, C.; Valera, L.; Gao, M. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob. Agents Chemother. 2010, 54, 3641–3650.
62. Bressanelli, S.; Tomei, L.; Roussel, A.; Incitti, I.; Vitale, R.L.; Mathieu, M.; De Francesco, R.; Rey, F.A. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc. Natl. Acad. Sci. USA 1999, 96, 13034–13039
63. Poveda, E.; Wyles, D.L.; Mena, Á.; Pedreira, J.D.; Castro-Inglesias, Á.; Cachay, E. Update on hepatitis C virus resistance to direct-acting antiviral agents. Antivir. Res. 2014, 108, 181–191.
64. Lontok, E.; Harrington, P.; Howe, A.; Kieffer, T.; Lennerstrand, J.; Lenz, O.; McPhee, F.; Mo, H.; Parkin, N.; Pilot-Matias, T. et al. Hepatitis C virus drug resistance-associated substitutions: State of the art summary. Hepatology 2015.
65. Qiu, P.; Cai, X.-Y.; Wang, L.; Greene, J.R.; Malcolm, B, Hepatitis C virus whole genome position weight matrix and robust primer design. BMC Microbiol. 2002, 2.
66. Hirotsu, Y.; Kanda, T.; Matsumura, H.; Moriyama, M.; Yokosuka, O.; Omata, M. HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1b. Hepatol. Int. 2015, 9, 424–430
67. Wu, S.; Kanda, T.; Nakamoto, S.; Jiang, X.; Miyamura, T.; Nakatani, S.M.; Ono, S.K.; Takahashi-Nakaguchi, A.; Gonoi, T.; Yokosuka, O. Prevalence of hepatitis C virus subgenotypes 1a and 1b in Japanese patients: Ultra-Deep sequencing analysis of HCV NS5B genotype-specific region. PLoS ONE 2013, 8, e73615.
68. Kuiken, C.; Hraber, P.; Thurmond, J.; Yusim, K. The hepatitis C sequence database in Los Alamos. Nucleic Acids Res. 2008, 36, D512–D516.
69. Zein, N.N. Clinical significance of hepatitis C virus genotypes. Clin. Microbiol. Rev. 2000, 13, 223–235.
70. Gouy, M.; Guindon, S.; Gascuel, O. SeaView version 4: A multiplatform graphical user interface for sequence alignment and phylogenetic tree building. Mol. Biol. Evol. 2010, 27, 221–224.
71. Hall, B.G. Building phylogenetic trees from molecular data with MEGA. Mol. Biol. Evol. 2013, 30, 1229–1235.
72. Stamatakis, A. RAxML version 8: A tool for phylogenetic analysis and post-analysis of large phylogenies. Bioinformatics 2014, 30, 1312–1313.
73. Struck, D.; Lawyer, G.; Ternes, A.M.; Schmit, J.C.; Bercoff, D.P. COMET: Adaptive context-based modeling for ultrafast HIV-1 subtype identification. Nucleic Acids Res. 2014, 42, e144
74. Liu, Y.; Chen, G.; Ying, M, Fuzzy Logic, Soft Computing and Computational Intelligence; Tsinghua University Press Springer. Eleventh International Fuzzy Systems Association World Congress: Beijing, China; Tsinghua University Press: Beijing, China, 2005; Volume III, p. 1288.
75. Eddy, S.R. Where did the BLOSUM62 alignment score matrix come from? Nat. Biotechnol. 2004, 22, 1035–1036.
76. Brocchieri, L.; Karlin, S. Conservation among HSP60 sequences in relation to structure, function and evolution. Protein Sci. 2000, 9, 476–486.
77. Pei, J.; Grishin, N.V. AL2CO: calculation of positional conservation in a protein sequence alignment. Boinformatics 2001, 17, 700–712.
78. Roebuck, K. Biochips: High-Impact Strategies—What You Need to Know: Definitions, Adoptions, Impact, Benefits, Maturity, Vendors; Emereo publishing: Aspley, Queensland, Australia, 2011; pp. 205–207.
79. Pond, S.L.; Frost, S.D.; Muse, S.V. HyPhy: Hypothesis testing using phylogenies. Bioinformatics 2005, 21, 676–679.
80. Nielsen, R.; Yang, Z. Likelihood models for detecting positively selected amino acid sites and applications to the HIV-1 envelope gene. Genetics 1998, 148, 929–936
81. Kosakovsky Pond, S.L.; Frost, S.D. Not so different after all: A comparison of methods for detecting amino acid sites under selection. Mol. Biol. Evol. 2005, 5, 1208–1222.
82. Kosakovsky Pond, S.L.; Poon, A.F.Y.; Frost, S.D.W. Chapter 14: Estimating selection pressures on alignments of coding sequences: Practice. In The Phylogenetic Handbook: A Practical Approach to Phylogenetic Analysis and Hypothesis Testing, 2nd ed.; Lemey, P., Salemi, M., Vandamme, A.M., Eds.; Cambridge University Press: New York, NY, USA, 2009; pp. 477–478.
83. Cummings, M.D.; Lindberg, J.; Lin, T.-I.; de Kock, H.; Lenz, O.; Lilja, E.; Felländer, S.; Baraznenok, V.; Nyström, S.; Nilsson, M. et al. Induced-fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/NS4A protease target. Angew. Chem. Int. Ed. 2010, 49, 1652–1655.
84. Romano, K.P.; Ali, A.; Royer, W.E.; Schiffer, C.A. Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Proc. Natl. Acad. Sci. USA 2010, 107, 20986–20991
85. Romano, K.P.; Ali, A.; Aydin, C.; Soumana, D.; Özen, A.; Deveau, L.M.; Silver, C.; Cao, H.; Newton, A.; Petropoulos, C.J. et al. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog. 2012, 8.
86. Meeprasert, A.; Hannongbua, S.; Rungrotmongkol, T. Key binding and susceptibility of NS3/4A serine protease inhibitors against hepatitis C virus. J. Chem. Inf. Model. 2014, 54, 1208–1217.
87. O’Boyle li, D.R.; Sun, J.H.; Nower, P.T.; Lemm, J.A.; Fridell, R.A.; Wang, C.; Romine, J.L.; Belema, M.; Nguyen, V.N.; Laurent, D.R. et al. Characterizations of HCV NS5A replication complex inhibitors. Virology 2013, 444, 343–354
88. Xue, W.; Jiao, P.; Yao, X. Molecular modeling and residue interaction network studies on the mechanism of binding and resistance of the HCV NS5B polymerase mutants to VX-222 and ANA598. Antivir. Res. 2014, 104, 40–51
89. Elfiky, A.A.; Elshemey, W.M.; Gawad, W.A.; Desoky, O.S. Molecular modeling comparison of the performance of NS5B polymerase inhibitor (PSI-7977) on prevalent HCV genotypes. Protein J. 2013, 32, 75–80
90. Wang, M.; Ng, K.K.; Cherney, M.M.; Chan, L.; Yannopoulos, C.G.; Bedard, J.; Morin, N.; Nguyen-Ba, N.; Alaoui-Ismaili, M.H.; Bethell, R.C. et al. Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibition. J. Biol. Chem. 2003, 278, 9489–9495